Focused On-demand Library for GEL complex subunit OPTI

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9BUV8

UPID:

RCAF1_HUMAN

Alternative names:

Obligate partner of TMCO1 insertase; Rab5-interacting protein; Respirasome Complex Assembly Factor 1

Alternative UPACC:

Q9BUV8; E1P5U0; O00605; Q5QPG6; Q5QPG7; Q9BT03; Q9BZU7; Q9UI05

Background:

GEL complex subunit OPTI, also known as Obligate partner of TMCO1 insertase, Rab5-interacting protein, and Respirasome Complex Assembly Factor 1, plays a crucial role in cellular processes. It is a component of the multi-pass translocon (MPT) complex, facilitating the insertion of multi-pass membrane proteins into the lipid bilayer. This protein also acts as an assembly factor for mitochondrial respiratory complexes, highlighting its importance in cellular respiration and energy production.

Therapeutic significance:

GEL complex subunit OPTI is linked to Craniofacial dysmorphism, skeletal anomalies, and impaired intellectual development syndrome 2, a disorder with significant genetic underpinnings. Understanding the role of GEL complex subunit OPTI could open doors to potential therapeutic strategies, offering hope for targeted interventions in this and related conditions.